

Amendments to the Claims:

Please cancel Claims 25, 26, 28, 30, 39, 43, 46-48 without prejudice to their prosecution in a continuation or divisional application. Please amend Claims 29, 31-33 and 40-42. Please add new Claims 49-64. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing:

1-26. (canceled)

27. (previously presented) A monoclonal antibody detecting and binding monospecifically human Mcm3 both immunohistologically and immunobiochemically, whereby the epitope of the monoclonal antibody of the hybridoma cell line with the deposit number DSM ACC2388 is detected.

28. (canceled)

29. (currently amended) ~~The monoclonal antibody according to Claim 25;~~ A monoclonal antibody specific for human Mcm3 which is produced by the hybridoma cell line with the deposit number DSM ACC2388.

30. (canceled)

31. (currently amended) ~~A hybridoma cell line according to Claim 30;~~ A hybridoma cell line which expresses a monoclonal antibody specific for human Mcm3, whereby the hybridoma cell line is the cell line with the deposit number DSM ACC2388.

32. (withdrawn-currently amended) A method of detecting human Mcm3 using the monoclonal antibody of ~~Claim 25~~ Claim 27.

33. (withdrawn-currently amended) A method for the immunohistological, immunocytological or immunobiochemical detection of human Mcm3 in a sample using the monoclonal antibody of ~~Claim 25~~ Claim 27.
34. (withdrawn) A method of Claim 33 wherein the sample is selected from serum, sputum, urine, or liquor.
35. (withdrawn) A method of Claim 33 wherein the sample is tissue or a fine needle aspiration product.
36. (withdrawn) A method of Claim 33 wherein the method is an immunobiochemical method selected from ELISA, RIA, Western Blot, Far Western Blot, immunoprecipitation and affinity chromatographic steps.
37. (withdrawn) A method of Claim 33 wherein the method is an immunocytological method selected from FACS and MACS.
38. (withdrawn) A method of Claim 33 wherein the method is an immunohistological method selected from fluorescence, radioactive, enzymatic and chemiluminescence methods.
39. (canceled)
40. (withdrawn-currently amended) A process for the production of purified human Mcm3 employing the monoclonal antibody according to ~~Claim 25~~ Claim 27.
41. (withdrawn-currently amended) A process for the production of purified human Mcm3, characterized in that the process comprises an affinity chromatography step with a monoclonal antibody according to ~~Claim 25~~ Claim 27.
42. (withdrawn-currently amended) A process for the production of purified human Mcm3 comprising an immunoprecipitation step with a monoclonal antibody according to ~~Claim 25~~ Claim 27.

43-48. (canceled)

- 49. (new) A diagnostic composition comprising a monoclonal antibody according to Claim 27.
- 50. (new) A diagnostic composition comprising a monoclonal antibody according to Claim 29.
- 51. (new) A diagnostic kit comprising the monoclonal antibody according to Claim 27.
- 52. (new) A diagnostic kit according to Claim 51 for the combined detection of the expression of Mcm3, Ki-67 and p27 for tumor diagnosis.
- 53. (new) A diagnostic kit comprising the monoclonal antibody according to Claim 29.
- 54. (new) A diagnostic kit according to Claim 52 for the combined detection of the expression of Mcm3, Ki-67 and p27 for tumor diagnosis.
- 55. (new) A method of detecting human Mcm3 using the monoclonal antibody of Claim 29.
- 56. (new) A method for the immunohistological, immunocytological or immunobiochemical detection of human Mcm3 in a sample using the monoclonal antibody of Claim 29.
- 57. (new) A method of Claim 56 wherein the sample is selected from serum, sputum, urine, or liquor.
- 58. (new) A method of Claim 56 wherein the sample is tissue or a fine needle aspiration product.
- 59. (new) A method of Claim 56 wherein the method is an immunobiochemical method selected from ELISA, RIA, Western Blot, Far Western Blot, immunoprecipitation and affinity chromatographic steps.

60. (new) A method of Claim 56 wherein the method is an immunocytological method selected from FACS and MACS.
61. (new) A method of Claim 56 wherein the method is an immunohistological method selected from fluorescence, radioactive, enzymatic and chemiluminescence methods.
62. (new) A process for the production of purified human Mcm3 employing the monoclonal antibody according to Claim 29.
63. (new) A process for the production of purified human Mcm3, characterized in that the process comprises an affinity chromatography step with a monoclonal antibody according to Claim 29.
64. (new) A process for the production of purified human Mcm3 comprising an immunoprecipitation step with a monoclonal antibody according to Claim 29.